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Abstract: In order to control the spread of COVID-19, people must adopt preventive behaviours 
that can affect their day-to-day life. People’s self-efficacy to adopt preventive behaviours to avoid 
COVID-19 contagion and spread should be studied. The aim of this study was to develop and 
psychometrically test the COVID-19 prevention, detection, and home-management self-efficacy 
scale (COVID-19-SES). We conducted an observational cross-sectional study. Six-hundred and 
seventy-eight people participated in the study. Data were collected between March and May 2020. 
The COVID-19-SES’ validity (content, criterion, and construct), reliability (internal consistency and 
test-retest reliability), and legibility were studied. The COVID-19-SES’ reliability was high 
(Cronbach’s alpha = 0.906; intraclass correlation coefficient = 0.754). The COVID-19-SES showed 
good content validity (scale’s content validity index = 0.92) and good criterion validity when the 
participants’ results on the COVID-19-SES were compared to their general self-efficacy (r = 0.38; p < 
0.001). Construct validity analysis revealed that the COVID-19-SES’ three-factor structure explained 
52.12% of the variance found and it was congruent with the World Health Organisation’s 
recommendations to prevent COVID-19 contagion and spread. Legibility analysis showed that the 
COVID-19-SES is easy to read and understand by laypeople. The COVID-19-SES is a 
psychometrically robust instrument that allows for a valid and reliable assessment of people’s self-
efficacy in preventing, detecting symptoms, and home-managing COVID-19. 
Keywords: COVID-19; psychometrics; self-efficacy 
 
1. Introduction 
The coronavirus disease (COVID-19) pandemic has caused a public health emergency 
worldwide [1]. COVID-19 is a potentially fatal disease caused by the severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) [1–3]. The clinical presentation of COVID-19 can vary widely. 
Whilst most patients seem to remain asymptomatic or present with mild to moderate upper 
respiratory tract illness [4,5], some develop severe viral pneumonia with respiratory failure that can 
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lead to death [1–3,6]. According to initial reports, many people with COVID-19 require 
hospitalisation or critical care [3,5,7–9]. Consequently, many countries have implemented strict 
public health measures to contain the spread of COVID-19 [10]. All these public health measures rely 
on the general public’s ability to adopt protective behaviours to avoid the contagion and spread of 
COVID-19 (for example, hand hygiene and social distancing) [10,11]. Since some of these public 
health measures are considered disruptive to people’s day-to-day life [12], their behavioural 
responses should be studied. However, little is known about people’s behavioural response to adopt 
all the recommended protective behaviours amidst the COVID-19 pandemic. 
Background 
Available evidence suggests that COVID-19 is a highly transmittable disease [13–15]. It is 
estimated that one case of COVID-19 could cause between 3 and 6 secondary cases during the 
outbreak [15]. In addition, early reports indicate that 7–16% of all COVID-19 cases may need 
hospitalisation and 5–12% could need ICU admission [3,5,7–9]. As evidence suggests that critical care 
capacities could be exceeded due to the COVID-19 pandemic [16,17], many governments worldwide 
have prioritised public health measures to control the spread of COVID-19 and flatten the peak of 
morbidity and mortality caused by the pandemic [10,18,19]. Following the World Health 
Organisation’s (WHO) advice [11,20], governments have urged the general public to implement 
protective behaviours to avoid the contagion and spread COVID-19 [10,18,19]. Some of these 
recommendations require individuals to be able to maintain social distancing, identify COVID-19 
symptoms, follow local protocols to seek healthcare advice, or even manage people with mild 
symptoms of COVID-19 at home under strict preventative measures to avoid the contagion and 
spread [11,20]. In addition, more waves of the COVID-19 pandemic are expected in the future [21,22], 
which may lead to having to adopt the above-mentioned protective behaviours for long periods of 
time. Therefore, healthcare professionals and behavioural scientists should study the general public’s 
protective behavioural responses amidst the COVID-19 pandemic [19]. 
According to the protection motivation theory (PMT), self-efficacy is considered a robust 
predictor of various health-related behaviours [23,24]. Bandura’s Social Cognitive Theory defines 
self-efficacy as one’s perceived ability to perform a target behaviour [25,26]. Research has shown that 
self-efficacy could predict the general public’s intention to engage in social distancing during a 
simulated pandemic caused by a respiratory infectious disease [24]. Furthermore, higher self-efficacy 
levels have been linked to taking other preventive measures during the SARS and influenza A 
pandemics (for example: handwashing, respiratory hygiene, and wearing a mask when having 
symptoms) [27–29]. In this regard, an individual’s self-efficacy in preventing, recognising symptoms, 
and home-managing COVID-19 should be studied and analysed. Nevertheless, although numerous 
instruments to assess behavioural responses during an epidemic have been used [28,30,31], there are 
no validated tools that would allow for a valid and reliable assessment of individuals’ self-efficacy in 
preventing, recognising symptoms, and home-managing a respiratory infectious disease. The aim of 
this study is to develop and psychometrically test the COVID-19 prevention, recognition, and home-
management self-efficacy scale (COVID-19-SES). 
2. Materials and Methods 
2.1. Design 
We completed the study in two phases following an observational cross-sectional design. In the 
first phase, we generated the tool’s items and pilot tested its content validity and reliability (i.e., 
internal consistency and test-retest reliability). In the second phase, we assessed the COVID-19-SES’ 
validity (i.e., content, criterion and construct validity), reliability (i.e., internal consistency and test-
retest reliability), and legibility. 
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2.2. Participants and Sampling 
We used a convenience sampling method to recruit 678 participants. All participants had to be 
at least 18 years old and accept voluntary participation before taking part in the study. In line with 
expert guidelines [32–34], we recruited between 50–60 participants for the pilot study (N = 56) and 
more than 10 participants per item for the final validation study (N = 622). Individuals who 
participated in the pilot study did not take part in the final validation study. 
2.3. Data Collection 
We collected data between March and May 2020 through online surveying. We generated an 
online questionnaire with three different sections. In the first section, we asked the participants to 
provide some demographic information (i.e., age, gender, level of education completed, occupation, 
history of respiratory or cardiovascular chronic conditions, perceived health, and experience of 
COVID-19 symptoms). In the second section, we asked the participants to complete the COVID-19-
SES. In the last section, we asked the participants to complete the General Self-Efficacy Scale (GSES) 
[35]. For the pilot study, the participants completed the same online questionnaire twice with a 2-
week interval. In the final validation study, the participants were asked to complete the COVID-19-
SES twice with a four-week interval. This allowed us to explore the COVID-19-SES test-retest 
reliability. 
2.4. Ethical Considerations 
The study was approved by the competent Ethics and Research Committee (protocol reference 
code: 76/2020). In the introductory section of the online survey, we provided information about the 
study (i.e., justification, aim, and methods), our research group, and participants’ right to withdraw at 
any point. We also explained how we were going to safeguard their anonymity and confidentiality. All 
data were treated according to the European legislation on data protection. Only three members of the 
research team had access to the raw data generated by the online survey platform (M.D.R.-F., I.D.-S., 
and M.C.-C.). They were in charge of coupling the participants’ test-retest responses and deleting the 
participants’ emails from the initial database. Then, the complete initial database (without email 
addresses) was handed to two different researchers (I.M.F.-M, M.M.L.-R.), who transferred all the data 
into a SPSS database and randomised the order of the responses. Once the SPSS database was created, 
the participants’ responses were deleted from the cloud and all the researchers’ laptops. Only the 
principal researcher has access to the blind SPSS database used for data analysis. All participants 
accepted voluntary participation before completing the online questionnaire by ticking a box that 
stated, “I agree to participate in the study described above and give my consent for my responses to be 
used with research purposes.” 
2.5. Phase 1: Item Generation and Pilot Study of the COVID-19-SES 
2.5.1. Item Generation 
According to the PMT, both the effectiveness of recommended behaviours and one’s self-efficacy 
to perform such behaviours strongly influence people’s motivation to engage in health-preventive 
conducts [23,24]. In line with the PMT, we generated the COVID-19-SES’ items based on the WHO’s 
recommended behaviours to protect oneself and others from the spread of COVID-19 [11,20]. Firstly, 
the research team analysed all the WHO recommendations and identified three categories in which 
to group the items: (1) prevention of COVID-19 spread and contagion, (2) early recognition of 
COVID-19 symptoms, and (3) home-management of patients with (or suspected) COVID-19 [11,20]. 
Secondly, we summarised the WHO recommendations and created the initial 19-item version of the 
COVID-19-SES. The 19 items comprising the COVID-19-SES were created by consensus. Following 
Bandura’s Social Cognitive Theory, people’s self-efficacy to adopt protective behaviours was 
measured in terms of their own capabilities to perform such behaviours [25,26]. In line with 
Bandura’s recommendations, the response options ranged from 0 (“completely sure that I cannot do 
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it”) to 100 (“completely sure that I can do it”) [25,36]. In addition, we added some degree of difficulty 
to all the items in order to avoid a ceiling effect (for example: “in any context” at the end of item 4 
and “even if my professional or social life are at stake” at the end of item 5) [37]. 
2.5.2. Pilot Study Methods 
Before conducting a final validation study, we explored the COVID-19-SES’ content validity 
using a panel of experts and then tested its reliability after administering it to a pilot sample (N = 56). 
Content Validity 
We followed Polit & Beck’s recommendations to explore the COVID-19-SES’ content validity 
[32]. Firstly, we recruited a panel of 14 experts from 5 different institutions in Spain and the UK. All 
the experts were either physicians or nurses with more than 10 years’ experience in public health, 
epidemiology, or infectious diseases. Secondly, we asked the experts to rate the 19 items comprising 
the COVID-19-SES depending on their relevance to measure people’s self-efficacy in preventing, 
detecting symptoms, and home-managing COVID-19 (1 = not relevant; 2 = somewhat relevant; 3 = 
quite relevant; 4 = highly relevant) [31]. Lastly, we calculated each item’s content validity index (i-
CVI) by adding the number of experts who rated the item as “quite relevant” or “highly relevant” 
and dividing it by the total number of experts [32]. We considered that an i-CVI ≥ 0.78 was 
appropriate [32]. 
Reliability 
To pilot test the COVID-19-SES, we administered the questionnaire to 56 participants and 
explored the tool’s internal consistency and test-retest reliability. We decided that an item positively 
contributed to the COVID-19-SES’ internal consistency if its corrected item-total correlation index (C-
ITC) was higher than 0.3 and the tool’s Cronbach’s alpha (α) did not increase significantly after 
removing that item [34]. Additionally, we computed the scale’s α and considered this as appropriate 
if it was higher than 0.7 [32]. To explore the COVID-19-SES’ test-retest reliability, we computed the 
intraclass correlation coefficient (ICC) between the participants’ scores on the test and on the retest 
we performed two weeks later. An ICC > 0.5 was deemed as appropriate [32]. 
2.6. Phase 2: Final Validity, Reliability, and Legibility Analysis of the COVID-19-SES 
Following Streiner & Kottner’s recommendations, we tested the COVID-19-SES’ validity (i.e., 
content, criterion and construct) and reliability (i.e., internal consistency and test-retest reliability) 
[34]. Additionally, we explored the scale’s legibility and developed an internal scoring system [32,38]. 
We analysed the data using IBM® SPSS Statistics® v.25 (IBM Company, Chicago, IL, USA). The 
COVID-19-SES was created and tested in Spanish. Four independent translators participated in the 
forward-backward procedure to translate the English version of the COVID-19-SES presented in this 
paper [39]. Two independent native English translators (proficient in Spanish) translated the COVID-
19-SES from Spanish to English. The small differences between their translations were reconciled by 
consensus and a single English version of the COVID-19-SES was created. Two independent native 
Spanish translators (proficient in English) performed a backtranslation of the COVID-19-SES English 
version into Spanish. Again, small differences in their backtranslation were reconciled by consensus. 
The research team and the translators examined the original COVID-19-SES, its English translation, 
and the backtranslation in Spanish. It was unanimously considered that the English version of the 
COVID-19-SES included in this paper respected the semantics of the original tool. 
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2.6.1. Validity 
Content Validity 
We explored the COVID-19-SES’ content validity following the same method as the one 
described in phase 1. In addition, we calculated the scale’s content validity index (S-CVI). We deemed 
appropriate a S-CVI higher than 0.78 [32]. 
Criterion Validity 
In order to explore the instrument’s criterion validity, we correlated the participants’ results on 
the COVID-19-SES with their results on the General Self-Efficacy Scale (GSES) [35]. Prior to this, we 
performed a normality test on the variable “mean_score_COVID”. The kurtosis (value = 1.78; SE = 
0.20), skewness (value = −1.21; SE = 0.10), Shapiro-Wilk test (W(622) = 0.91; p < 0.001), and histogram 
showed that the variable was not normally distributed [40]. Therefore, we calculated the Spearman 
correlation coefficient (r) between the participants’ scores on the COVID-19-SES and on the GSES 
[32,41,42]. A correlation coefficient (r) higher than 0.3 was considered acceptable. 
Construct Validity 
To explore the COVID-19-SES’ construct validity, we carried out an exploratory factor analysis 
(EFA) with principal axis factoring (PAF) and varimax rotation. Firstly, we computed the Kaiser-
Mayer-Olkin test (KMO) and Bartlett’s test of sphericity to explore the adequacy of the analysis. A 
KMO > 0.7 and a significant Bartlett’s test (χ2) were considered as indicators of the appropriateness 
to conduct an EFA [32,41,43]. The number of factors extracted as underlying dimensions of the 
COVID-19-SES was determined by: (1) the point where the curve of the scree plot clearly levelled off 
and (2) the number of factors with eigenvalues equal or higher than 1 [32,41,43]. Items were 
considered to be part of a factor (or dimension) when their factor-loading coefficient was ≥ 0.45 [43]. 
2.6.2. Reliability 
We explored the COVID-19-SES’ reliability (i.e., internal consistency and test-retest reliability) 
following the same method as the one described in phase 1. Furthermore, we studied the correlations 
(Spearman’s correlation coefficient) between the COVID-19-SES and all its sub-dimensions [32]. 
2.6.3. Legibility 
We analysed the COVID-19-SES’ legibility using the INFLESZ scale, which measures the 
difficulty of healthcare-related texts directed at laypeople [44]. According the INFLESZ scale, texts 
can be very easy (> 80), quite easy (66–80), normal (56–65), somewhat difficult (40–55), or very difficult 
(< 40) [44]. In addition, we included a text box in the online questionnaire for participants to express 
whether they had any difficulties reading, understanding, or completing the COVID-19-SES. 
2.6.4. Scoring and Interpretation System 
In order to facilitate the interpretation of the results yielded from the COVID-19-SES, we 
developed an internal scoring system following the experts’ recommendations [32,38]. In this regard, 
we calculated the participants’ mean score on the COVID-19-SES and its standard deviation (SD), 
which allowed us to create the following five scoring categories: (1) very low self-efficacy = scores > 
2 SD below the mean, (2) low self-efficacy = scores between 1–2 SD below the mean, (3) moderate self-
efficacy = scores ≤ 1 SD below the mean, (4) high self-efficacy = scores ≤ 1 SD above the mean, and (5) 
very high self-efficacy = scores > 1 SD above the mean. 
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3. Results 
3.1. Pilot Study Results 
Table 1 summarises the results of the pilot study. The experts considered that all the items were 
relevant to measure the intended construct (i-CVI > 0.78) and they were all kept as part of the COVID-
19-SES that we administered to the pilot sample (N = 56). The COVID-19-SES’ α was 0.905 and it 
would not have increased if we had removed any of the items. All the items’ C-ITC was higher than 
0.3. Furthermore, the average measure ICC was 0.917 with a 95% confidence interval from 0.86 to 0.91 
(F(55,55) = 12.00, p < 0.001). All items were kept as part of the COVID-19-SES for its final validation 
study. 
Table 1. Internal consistency and content validity results from the pilot study (N = 56). 
  i-CVI 1 
NP-SES’ 
Alpha if Item 
Deleted 
C-ITC 2 
Item 1. Regularly and thoroughly wash my hands with soap 
and water or clean them with an alcohol-based hand 
sanitiser wherever I go. 
1 0.906 0.316 
Item 2. Cover my mouth and nose with a tissue or my bent 
elbow every time I cough or sneeze. 
1 0.904 0.394 
Item 3. Not touch my eyes, nose, or mouth under any 
circumstances. 
0.93 0.903 0.475 
Item 4. Maintain at least one metre distance between myself and 
others at all time. 
0.93 0.903 0.459 
Item 5. Avoid getting in contact with large groups of people 
even if my professional and social life are at stake. 
1 0.902 0.490 
Item 6. Only go outside when permitted and following the 
government’s directions. 
1 0.905 0.373 
Item 7. Identify if I have symptoms of COVID-19 quickly after 
they appear. 
0.93 0.899 0.657 
Item 8. Decide when symptoms require me to either call the 
COVID-19 emergency phone number or go to see a 
doctor, following the recommendations from the health 
authorities. 
0.93 0.905 0.389 
Item 9. Decide when my situation requires me to either call the 
COVID-19 emergency phone number or continue with 
my normal life, according to recommendations from 
health authorities. 
0.86 0.903 0.466 
Item 10. Call the correct phone number that the health authorities 
of my region have enabled for COVID-19 emergencies. 
1 0.902 0.505 
Item 11. Isolate persons with symptoms in a well-ventilated room 
for exclusive use, no matter how hard this may be. 
0.86 0.901 0.537 
Item 12. Ensure that the waste from the person with symptoms 
goes into a self-closing rubbish bin with a sealed bag, 
which is not shared with other household members. 
0.93 0.898 0.644 
Item 13. Reserve, if possible, a bathroom for the exclusive use of 
the person with symptoms. 
0.79 0.907 0.461 
Item 14. Keep the door to the room of the person with symptoms 
closed at all times. 
0.93 0.896 0.703 
Item 15. Limit the movement of the person with symptoms in the 
house, even if it is sometimes difficult. 
0.93 0.892 0.828 
Item 16. Maintain a minimum distance of 1 metre from the 
person with symptoms at all times. 
0.86 0.894 0.753 
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Item 17. Ensure that the person with symptoms wears a mask 
and gloves every time they leave the room, without 
exception. 
0.79 0.898 0.653 
Item 18. Carry out an exhaustive daily cleaning following 
experts’ recommendations regarding material, 
disinfectant products, water temperature, and important 
surfaces. 
1 0.894 0.798 
Item 19. Remove the waste from the person with symptoms 
following experts’ safety recommendations. 
0.93 0.896 0.707 
1 i-CVI = Content Validity Index of each item; 2 C-ITC = Corrected Item-Total Correlation. 
3.2. Participants and Descriptive Data 
Table 2 summarises the participants’ characteristics. The participants’ mean age was 35.80 (SD = 
13.89) and they were 68.8% female (n = 428). Almost 40% of the participants had completed primary 
or secondary education, 31% had completed vocational training, and around 30% had completed a 
university degree, masters or PhD. In terms of participants’ occupation, almost 25% were 
unemployed (n = 153) and 20% were healthcare professionals (n = 125). The majority of participants 
had not been diagnosed with a respiratory or cardiovascular chronic condition (n = 543) and had not 
experienced COVID-19 symptoms (n = 411). Most participants declared their health to be good (n = 
352) or very good (n = 202). Tables 3 and 4 show the participants’ mean score on each item and each 
sub-dimension of the COVID-19-SES. 
Table 2. Participants’ sociodemographic characteristics. 
Characteristics 
Sample (N = 622) 
M ± SD 
Age (years) 35.80 ± 13.89 
 N (%) 
Gender  
Female 428 (68.8) 
Male 190 (30.5) 
Highest educational level completed  
Primary 70 (11.3) 
Secondary 167 (26.8) 
Vocational qualification 195 (31.4) 
University degree 157 (25.2) 
Masters or PhD 33 (5.3) 
Occupation  
Unemployed 153 (24.6) 
Healthcare professional 125 (20.1) 
Qualified worker 222 (35.7) 
Non-qualified worker 111 (17.8) 
Retired 11 (1.8) 
Have you experienced COVID-19 symptoms? 
Yes 18 (2.9) 
No 411 (66.1) 
I am not sure 193 (31.0) 
Respiratory or cardiovascular chronic condition 
Yes 79 (12.7) 
No 543 (87.3) 
Perceived general health  
Very poor 1 (0.2) 
Poor 5 (0.8) 
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Normal 62 (10.0) 
Good 352 (56.6) 
Very good 202 (32.5) 
M = Mean; SD = Standard Deviation. 
Table 3. Internal consistency and content validity results from the final validation study (N = 622). 
  i-CVI NP-SES’ Alpha if Item Deleted C-ITC M ± SD 
Item 1. Regularly and thoroughly wash my […]. 1 0.906 0.364 88.90 ± 17.15 
Item 2. Cover my mouth and nose with a […]. 1 0.905 0.448 92.30 ± 14.15 
Item 3. Not touch my eyes, nose or mouth […]. 0.93 0.905 0.425 68.30 ± 24.85 
Item 4. Maintain at least one metre […]. 0.93 0.906 0.397 79.70 ± 22.55 
Item 5. Avoid getting in contact with large […]. 1 0.907 0.329 90.30 ± 17.94 
Item 6. Only go outside when permitted […]. 1 0.905 0.423 94.00 ± 14.12 
Item 7. Identify if I have symptoms […]. 0.93 0.904 0.459 79.60 ± 20.99 
Item 8. Decide when symptoms require […]. 0.93 0.904 0.480 84.10 ± 20.49 
Item 9. Decide when my situation requires […]. 0.86 0.903 0.513 84.40 ± 19.66 
Item 10. Call the correct phone number […]. 1 0.904 0.477 89.20 ± 18.23 
Item 11. Isolate the person with symptoms […]. 0.86 0.896 0.744 82.20 ± 24.73 
Item 12. Ensure that the waste from the […]. 0.93 0.897 0.701 77.90 ± 28.03 
Item 13. Reserve, if possible, a bathroom […]. 0.79 0.908 0.464 72.10 ± 37.32 
Item 14. Keep the door to the room of the […]. 0.93 0.897 0.718 81.10 ± 27.63 
Item 15. Limit the movement of the person […]. 0.93 0.895 0.778 81.70 ± 25.46 
Item 16. Maintain a minimum distance […]. 0.86 0.897 0.719 79.90 ± 26.44 
Item 17. Ensure that the person with […]. 0.79 0.900 0.626 81.50 ± 27.77 
Item 18. Carry out an exhaustive daily […]. 1 0.897 0.741 82.90 ± 23.12 
Item 19. Remove the waste from the person […]. 0.93 0.896 0.743 81.40 ± 24.40 
i-CVI = Content Validity Index of each item; C-ITC = Corrected Item-Total Correlation; M = Mean; SD 
= Standard Deviation. 
3.3. Validity 
Content validity analysis showed that all the items’ i-CVI > 0.78 (See Table 3) and the COVID-
19-SES’ S-CVI was 0.92. In terms of criterion validity, our analysis indicated that the participants’ 
scores on the COVID-19-SES moderately correlated with their scores on the GSES (r = 0.38; p < 0.001). 
Regarding the COVID-19-SES’ construct validity, the KMO test (KMO = 0.904) and the Bartlett’s test 
of sphericity (χ2(171) = 6585.145; p < 0.001) evidenced the appropriateness for an EFA to be conducted. 
Our PAF analysis showed that the COVID-19-SES has three underlying factors that explained 52.12% 
of the cumulative variance found (see Table 4. These three factors presented an eigenvalue > 1 and 
all the items loaded onto one factor with a factor-loading coefficient > 0.45. Table 4 shows the COVID-
19-SES’ dimensional structure: [Factor 1] prevention of COVID-19 contagion and spread, [Factor 2] 
recognition of COVID-19 symptoms, and [Factor 3] home-management of people with COVID-19 
symptoms. 
Table 4. Exploratory factor analysis results and structure of the COVID-19-SES (N = 622). 
  
FACTOR 
1 2 3 
Prevention of COVID-19 contagion and spread 
Item 1 0.090 0.172 0.533 
Item 2 0.189 0.138 0.569 
Item 3 0.185 0.164 0.518 
Item 4 0.191 0.058 0.531 
Item 5 0.093 0.020 0.594 
Item 6 0.208 0.180 0.451 
Recognition of COVID-19 symptoms 
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Item 7 0.183 0.648 0.167 
Item 8 0.133 0.891 0.143 
Item 9 0.188 0.842 0.144 
Item 10 0.231 0.543 0.208 
Home-management of people with COVID-19 symptoms 
Item 11 0.803 0.160 0.193 
Item 12 0.704 0.146 0.256 
Item 13 0.555 0.076 0.057 
Item 14 0.803 0.157 0.136 
Item 15 0.873 0.158 0.162 
Item 16 0.757 0.133 0.228 
Item 17 0.622 0.171 0.222 
Item 18 0.644 0.249 0.358 
Item 19 0.679 0.231 0.324 
% of variance 26.31 13.66 12.15 
% of cumulative variance 26.31 39.97 52.12 
The factor loading figures in bold indicate which factor each item loads onto. 
3.4. Reliability 
Table 3 presents the items’ C-ITC and the scale’s α if the items were removed. The COVID-19-
SES’ α was 0.906, all the items’ C-ITC > 0.3, and the scale’s α would not have increased if we had 
removed any of the items. Additionally, all the sub-dimensions’ α was higher than 0.70 (see Table 5). 
Regarding test-retest reliability, 85% of participants completed the retest after 4 weeks (n = 531) and 
we found that the average measure ICC was 0.757 with a 95% confidence interval from 0.71 to 0.80 
(F(530,530) = 4.12, p < 0.001). Lastly, Table 6 shows that all the correlations between the participants’ 
mean total score for the COVID-SES-19 and its sub-dimensions were higher than 0.30. 
Table 5. Cronbach’s alpha and descriptive data for the COVID-19-SES and its sub-dimensions. 
 Cronbach’s Alpha M ± SD 
COVID-19-SES 0.905 83.32 ± 13.24 
Prevention of COVID-19 contagion and spread 0.726 85.58 ± 12.27 
Recognition of COVID-19 symptoms 0.852 84.31 ± 16.54 
Home-management of people with COVID-19 symptoms 0.919 80.09 ± 13.24 
M = Mean; SD = Standard Deviation. 
Table 6. Correlations between COVID-19-SES and its sub-dimensions. 
 Prevention Recognition Home-Management 
Prevention - - - 
Recognition 0.389 * - - 
Home-management 0.491 * 0.444 * - 
Total COVID-19-SES 0.721 * 0.746 * 0.849 * 
* significant at the 0.01 level (2-tailed). 
3.5. Legibility 
The results from the INFLESZ analysis (score = 68.04) showed that the COVID-19-SES was “quite 
easy” to read and understand by laypeople. Furthermore, none of the participants reported any 
difficulties to read, understand, or complete the scale. 
3.6. Scoring and Interpretation System 
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The participants’ mean score on the COVID-19-SES was 83.32 (SD = 13.24). We developed the 
following internal scoring system: (1) very low self-efficacy = scores below 55, (2) low self-efficacy = 
scores 55–68, (3) moderate self-efficacy = scores 69–82, (4) high self-efficacy = scores 83–96, and (5) 
very high self-efficacy = scores above 96. 
4. Discussion 
The aim of this study was to develop and psychometrically test the COVID-19 prevention, 
recognition, and home-management self-efficacy scale (COVID-19-SES). Bandura’s theoretical 
framework suggests that higher levels of self-efficacy indicate individuals’ higher motivation 
towards carrying out a given task [25,26]. In fact, self-efficacy has been linked to better preventive 
behavioural responses in a pandemic outbreak [24,27–29]. In an attempt to control the pandemic, 
many governments have urged the general public to confine themselves at home and/or to adopt 
protective behaviours that can alter their day-to-day life [10,12,18,19]. Developing an instrument for 
the assessment of individuals’ self-efficacy to adopt preventive measures would allow healthcare 
professionals to explore the general public’s behavioural responses amidst the public health 
emergency generated by the COVID-19 pandemic [19]. 
When a psychometric instrument is developed, we have to carefully examine its validity and 
reliability [32,34]. Whilst validity refers to the instrument’s ability to actually measure the construct 
that it intends to measure [33,41], reliability refers to its ability to produce accurate and consistent 
results across time [32,33]. In this study, we assessed the COVID-19-SES’ validity and reliability. 
Furthermore, we analysed its legibility and created a scoring system to facilitate the interpretation of 
the results [32,38]. 
Regarding the COVID-19-SES’ validity, we analysed its content, criterion, and construct validity 
[34]. A panel of 14 independent experts critically reviewed the COVID-19-SES and decided that all 
the items comprising the tool were relevant to measure individuals’ self-efficacy in preventing, 
recognising symptoms and home-managing COVID-19 [41]. In terms of criterion validity, our 
analysis showed that the participants’ results on the COVID-19-SES moderately correlated to their 
results on the general self-efficacy scale. Self-efficacy is situation-specific and people can be more or 
less efficacious in some realms than others [25,45]. Although both instruments assess people’s self-
efficacy, they both refer to very different realms in their lives and this could explain why we found a 
moderate correlation between them. With regard to our construct validity analysis, we found that the 
COVID-19-SES has a three-dimension structure. The three dimensions of the COVID-19-SES allow 
for the assessment of people’s self-efficacy in preventing the contagion and spread of COVID-19, 
recognising COVID-19 symptoms, and home-managing patients with mild COVID-19 symptoms. 
These three dimensions are in line with the WHO’s recommendations for the general public to avoid 
the contagion and spread of COVID-19 [11,20]. In general, the results from our validity analysis 
suggest that the COVID-19-SES is a valid instrument for assessing the general public’s self-efficacy 
in their ability to adopt preventive behaviours to prevent, recognise symptoms, and home-manage 
COVID-19 [32,33,41]. In terms of reliability, our analysis has shown that all the items of the COVID-
19-SES contribute to its strong internal consistency. Additionally, our test-retest reliability analysis 
suggests that the COVID-19-SES can yield consistent results across time. This evidence indicates that 
the COVID-19-SES can measure the general public’s self-efficacy in preventing, recognising 
symptoms, and home-managing COVID-19 in a reliable and consistent manner [32,33,41]. 
Contributing to the good psychometric properties of the tested instrument, our legibility analysis 
showed that the COVID-19-SES is easy to read, understand, and complete by laypeople [44]. Lastly, 
our descriptive analysis showed that our participants are highly efficacious in preventing, 
recognising symptoms, and home-managing COVID-19. This could be related to the fact that the 
Spanish government has implemented strict measures to oblige the general public to implement 
protective measures against the contagion and spread of COVID-19 [19]. Future research should use 
the COVID-19-SES to collect data about different populations’ self-efficacy in order to deepen our 
understanding of its mediating effect on people’s behavioural responses to the pandemic over time. 
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Although we conducted a methodologically rigorous study, we need to highlight some 
limitations. Firstly, our sample was selected through a convenience sampling technique, which 
means that our results cannot be generalised. Although participants stated they were from 33 
different provinces in Spain, we suggest that future studies use a stratified sampling method to 
recruit a representative sample. Secondly, our sample mainly comprised of young, healthy adults. It 
is important to test the COVID-19-SES’ main psychometric properties amongst samples of people 
with specific clinical, social, or behavioural backgrounds. Thirdly, the COVID-19-SES was developed 
and validated in Spanish. Although the instrument complies with the WHO’s recommendations to 
prevent the contagion and spread of COVID-19, its use in a different language should be preceded 
by a psychometric evaluation. Fourthly, due to the strict lockdown measures implemented by the 
Spanish government during the COVID-19 outbreak, we could only collect data through online 
surveying. Populations with limited access to the Internet or social media may be unrepresented. 
Lastly, data were collected through self-administered questionnaires. Since the Spanish government 
decreed the state of alarm and people were obliged to comply with some of the preventive behaviours 
reflected in the COVID-19-SES [12], the study participants could have fallen into social desirability 
bias. 
5. Conclusions 
Following an exhaustive assessment, the COVID-19-SES has shown to have good psychometric 
properties. Our results suggest that the COVID-19-SES is a valid, reliable, and legible instrument that 
would allow for the assessment of people’s self-efficacy in preventing, recognising symptoms, and 
home-managing COVID-19. Healthcare professionals and behavioural scientists should use the 
COVID-19-SES to study both people’s level of confidence in their ability to adopt protective 
behaviours amidst future waves of the pandemic as well as the relationship between self-efficacy and 
people’s behavioural responses in a pandemic caused by an infectious respiratory disease. The results 
yielded from the COVID-19-SES could provide information about people’s motivation to comply 
with the recommended protective behaviours. Therefore, healthcare professionals could use the 
COVID-19-SES when they require patients with (or suspected) mild COVID-19 symptoms and 
relatives to isolate themselves at home. Low levels of self-efficacy in preventing, recognising 
symptoms, and home-managing COVID-19 could indicate the need for health education 
interventions. Future studies should focus on testing the COVID-19-SES amongst different 
populations in different socio-cultural contexts and confirming the tool’s dimensionality. 
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